BioVie Inc. (NASDAQ:BIVI) Reports Phase 2 ADDRESS—LC Topline Results
BioVie reported Phase 2 ADDRESS—LC topline data: no endpoints hit significance in the full ITT population, while pre—specified high—symptom subgroups showed statistically significant improvements on multiple measures. Safety was similar to placebo.Material DetailsContext by AI AnalystThis is an exp…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.